Lantern Pharma (NASDAQ:LTRN) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Lantern Pharma (NASDAQ:LTRN) posted its earnings results on Thursday. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03), Zacks reports.

Lantern Pharma Price Performance

Shares of Lantern Pharma stock traded down $0.13 during trading on Friday, reaching $3.60. 34,671 shares of the stock traded hands, compared to its average volume of 83,932. Lantern Pharma has a 52-week low of $2.79 and a 52-week high of $10.06. The business has a fifty day simple moving average of $4.26 and a two-hundred day simple moving average of $3.78. The company has a market capitalization of $38.77 million, a price-to-earnings ratio of -2.02 and a beta of 1.64.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.